Opendata, web and dolomites

GlyCan

Innovative Glycan-based analysis for Cancer diagnostics

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 GlyCan project word cloud

Explore the words cloud of the GlyCan project. It provides you a very rough idea of what is the project "GlyCan" about.

confirm    assay    founder    95    lacks    biomarker    co    worldwide    6m    economic    accurately    clinics    patients    centres    advisors    sending    simplicity    healthy    ing    glycan    home    opinion    grant    clinically    consists    innovative    needless    proteins    dr    biopsy    quantifying    antigen    tkac    annually    dna    false    hospital    epo    advantage    biomolecules    societal    market    prior    preliminary    positive    dre    dx    examination    mrna    scientific    company    owned    detect    circulating    biomarkers    serum    psa    discriminates    instead    erc    glycanostics    quantify    business    2nd    deaths    rectal    rate    biopsies    competitive    check    suspicious    blood    b2b    cancer    accuracy    screening    covered    competitors    undergo    representing    prostate    homes    pca    jan    members    366k    kit    sick    digital    75    74    b2c    core    launched    mistreatment    protein    team    patent    examinations    diagnostic    throughput    cso    311532    commercial    combined    pain    granted    burden    invasive    diagnostics    outcome   

Project "GlyCan" data sheet

The following table provides information about the project.

Coordinator
GLYCANOSTICS SRO 

Organization address
address: DUBRAVSKA CESTA 9
city: BRATISLAVA
postcode: 845 38
website: n.a.

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Slovakia [SK]
 Project website https://www.glycanostics.com/
 Total cost 71˙429 €
 EC max contribution 50˙000 € (70%)
 Programme 1. H2020-EU.3. (PRIORITY 'Societal challenges)
2. H2020-EU.2.3. (INDUSTRIAL LEADERSHIP - Innovation In SMEs)
3. H2020-EU.2.1. (INDUSTRIAL LEADERSHIP - Leadership in enabling and industrial technologies)
 Code Call H2020-SMEInst-2018-2020-1
 Funding Scheme SME-1
 Starting year 2019
 Duration (year-month-day) from 2019-02-01   to  2019-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    GLYCANOSTICS SRO SK (BRATISLAVA) coordinator 50˙000.00

Map

 Project objective

Worldwide, there are 1.6M new prostate cancer (PCa) cases with 366k deaths annually. Novel PCa biomarkers are needed since the best current PCa biomarker (prostate specific antigen (PSA)) lacks PCa diagnostic accuracy often resulting in mistreatment of PCa patients. The false-positive rate of PSA in blood serum is ~75%. PSA test is applied together with digital rectal examination (DRE) for preliminary screening. If the combined results are suspicious, the patients undergo a biopsy to confirm PCa. Yet, there are 74% of needless biopsies representing a significant pain for PCa patients and societal/economic burden.

Based on a great commercial outcome from the ERC grant (311532) granted to Dr. Jan Tkac (co-founder/CSO of Glycanostics), the company has developed an innovative, non-invasive, early PCa diagnostics using blood serum. Instead of quantifying PSA, the innovative PCa diagnostic assay detect glycan changes on PSA protein (it discriminates between “healthy” PSA and “sick” PSA and accurately quantify the clinically relevant “sick” PSA). The technology is covered by two EPO patent applications owned by the company. The PCa diagnostic test with 95% accuracy will be applied as a 2nd opinion test in case of suspicious results from PSA & DRE examinations prior sending to a biopsy. PCa DX kit will be launched for clinics/hospital & cancer centres (B2B) and Prostate check home test for user-friendly application at homes (B2C).

Our PCa diagnostic technology is unique compared to our competitors focusing on analysis of other complex biomolecules such as a level of proteins, mRNA and circulating DNA. Moreover, we have competitive advantage over competitors in terms of cost per sample, assay accuracy, simplicity of the assay enabling the home testing and high-throughput.

Glycanostics consists of 7 core team members, 4 business and 4 scientific advisors making a great and highly experienced team that will bring these innovative PCa early diagnostic products to the market.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "GLYCAN" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "GLYCAN" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.3.;H2020-EU.2.3.;H2020-EU.2.1.)

Preemie (2019)

Personalised nutrition of low-birth-weight infants

Read More  

Magnesys (2019)

Efficient filtering of metallic impurities in food processing

Read More  

COPI (2020)

Carbon Offset Plug-in

Read More